A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

July 21, 2020

Study Completion Date

December 20, 2021

Conditions
Multiple Myeloma in Relapse
Interventions
DRUG

Daratumumab

"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."

Trial Locations (6)

K7L 2V7

Kingston Health Sciences Centre, Kingston

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H1T 2M4

Hôpital Maisonneuve-Rosemont, Montreal

H4A 3J1

McGill University Health Centre, Montreal

G1J 1Z4

Hôpital de l'Enfant-Jésus, Québec

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

All Listed Sponsors
lead

Canadian Myeloma Research Group

OTHER

NCT03697629 - A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter